Advertisement
Table 3 Sensitivity analysis parameters
| Parameter | One-way sensitivity analysis | PSA | ||
|---|---|---|---|---|
| Base case value | Range | SD | Distribution | |
| FOLFOX4 survival (PFS and OS) | 100% | 80–120% | 20% | Normal |
| Sorafenib survival (PFS and OS) | 100% | 80–120% | 20% | Normal |
| Sorafenib monthly cost | 3777 | 3021–4532 | 1126 | Gamma |
| FOLFOX4 monthly cost | 1865 | 1492–2238 | 373 | Gamma |
| Dosage per cycle Oxaliplatin | 138 | 110–166 | 28 | Normal |
| Dosage per cycle 5-FU | 3247 | 2597–3896 | 649 | Normal |
| Dosage per cycle L-FC | 649 | 519–779 | 130 | Normal |
| Utility PFS | 0.76 | 0.61–0.91 | 0.152 | Normal |
| Utility PD | 0.68 | 0.54–0.82 | 0.136 | Normal |
| General ward cost per cycle | 39 | 19–78 | 8 | Gamma |
| AE costs | 100% | 50/200% | 20% | Gamma |
| Cost of HCC progression test (RMB) | 155 | 78–310 | 93 | Gamma |
| Proportion of FOLFOX4 general ward | 100% | 50% | N/A | N/A |
| Discount rate | 5% | 0–8% | N/A | N/A |
